SutroVax

OverviewSuggest Edit

SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases.
SutroVax conjugate vaccines are developed utilizing the Company’s exclusive rights to Sutro Biopharma’s Xpress CF Platform, a cell-free protein synthesis technology. The platform represents a major advancement over conventional conjugate vaccine production methods, by enabling precise and consistent conjugation of antigens to site-specific locations on a protein carrier that do not impede T-cell help resulting in higher-potency conjugates. SutroVax is utilizing these more potent conjugates to develop a broader-spectrum PCV product.

TypePrivate
Founded2013
HQFoster City, US
Websitesutrovax.com

Latest Updates

Employees (est.) (Jan 2020)49(+3%)

Key People/Management at SutroVax

Grant Pickering

Grant Pickering

President & Chief Executive Officer, Director and Founder
Jeff Fairman

Jeff Fairman

Vice President of Research and Founder
Durga P. Bobba

Durga P. Bobba

Chief Business Officer
Alan Kimura

Alan Kimura

Consulting Chief Medical Officer
Elaine D Sun

Elaine D Sun

CFO
Paul W Sauer

Paul W Sauer

Vice President, Process Development & Manufacturing
Show more

SutroVax Office Locations

SutroVax has an office in Foster City
Foster City, US (HQ)
353 Hatch Dr
Show all (1)

SutroVax Financials and Metrics

Summary Metrics

Founding Date

2013

SutroVax total Funding

$171 m

SutroVax latest funding size

$85 m

Time since last funding

2 years ago

SutroVax investors

SutroVax's latest funding round in June 2018 was reported to be $85 m. In total, SutroVax has raised $171 m
Show all financial metrics

SutroVax Online and Social Media Presence

Embed Graph

SutroVax News and Updates

Eyeing the most lucrative vaccine market, SutroVax nabs $85M and Moncef Slaoui as chairman

With ambitions to take on global vaccine leaders in the industry's top field, SutroVax is revving up operations with Series C funding and a prominent Big Pharma ex as chair. The target? Pneumococcal vaccines such as Pfizer’s Prevnar.

Corporate Investment In Pharma Startups On The Rebound

Many of the most active investors in pharmaceutical startups are venture capital firms such as OrbiMed Advisors, NEA, or Versant Ventures. But direct investment from corporate entities and corporate venture arms has been trending up for the past 4 years. These … Continued

SutroVax Blogs

SutroVax Receives CARB-X Award for Up to $15 Million to Develop a Universal Vaccine to Prevent Group A Streptococcus Infections

Proprietary conserved antigen with potential to provide broad protection against strains of Group A Strep licensed from University of California San Diego Foster City, CA, September 3, 2019 – SutroVax,...

SutroVax Frequently Asked Questions

  • When was SutroVax founded?

    SutroVax was founded in 2013.

  • Who are SutroVax key executives?

    SutroVax's key executives are Grant Pickering, Jeff Fairman and Durga P. Bobba.

  • How many employees does SutroVax have?

    SutroVax has 49 employees.

  • Who are SutroVax competitors?

    Competitors of SutroVax include Biogen, MyoKardia and Reata Pharmaceuticals.

  • Where is SutroVax headquarters?

    SutroVax headquarters is located at 353 Hatch Dr, Foster City.

  • Where are SutroVax offices?

    SutroVax has an office in Foster City.

  • How many offices does SutroVax have?

    SutroVax has 1 office.